Eli Lilly has begun terminating federally mandated 340B drug price discounts to hospitals failing to submit required claims documentation, marking a significant shift toward stricter manufacturer enforcement of the discount programme. The action affects dozens of institutions and signals growing pharmaceutical industry pressure on healthcare providers to demonstrate accountability and transparency in a programme designed to expand medication access for uninsured and low-income patients.
The 340B Drug Pricing Program requires eligible healthcare institutions—including safety-net hospitals and critical access facilities—to report drug utilization data to ensure compliance with federal regulations. However, many hospitals struggle with the administrative and technical demands of data reporting, creating friction between manufacturers seeking verification and institutions facing resource constraints.
This enforcement action raises questions about programme sustainability: as drug makers tighten verification requirements, smaller and under-resourced hospitals may face mounting pressure to invest in IT infrastructure or risk losing vital medication discounts for vulnerable patient populations. Read the full article on GMJ Newsroom.
Was this article helpful?
